Correlation between ACE gene I/D polymorphism and clinical efficacy of iptakalim in Chinese Han hypertensive population

Abstract

Abstract: AIM: To study the correlation between angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and the clinical efficacy of iptakalim in a Chinese Han hypertensive population.METHODS: The ACE I/D polymorphism of 162 Chinese Han hypertensive patients treated with iptakalim for 8 weeks was determined by the polymerase chain reaction technique.RESULTS: Among the 162 cases of hypertensive patients, the frequencies of II, ID, and DD were 40.1%, 46.3%, and 13.6%, respectively. The pretreatment SBP and DBP were (153±13) mm Hg and (100±4) mm Hg, respectively. The pretreatment DBP were not different in the three groups, while the pretreatment SBP were larger in patients with the DD genotype than those with the II and ID genotypes (P<0.05). The posttreatment SBP and DBP were (142±13) mm Hg and (89±9) mm Hg, respectively. The changes of SBP and DBP by iptakalim were significant (P<0.001). The posttreatment SBP were similar in the three groups, while a greater decrease in DBP was observed in patients with the II genotype than those with the ID genotype (P<0.05). The clinical efficacy was 66.67% after iptakalim administration in 162 patients. The clinical efficacy of the II genotype group (75.38%) was higher than that of the ID genotype group (58.67%) (P<0.05).CONCLUSION: Iptakalim is a new and effective antihypertensive drug. The patients with the genotype II have better clinical efficacy.

Key words: Iptakalim, Hypertension, ACE, Gene polymorphism

CLC Number:

R969

DUAN Rui-feng, CUI Wen-yu, GAO Hong-yan, WANG Xiao-pei, HU Sheng-kai, LIU Wei, WANG Hai. Correlation between ACE gene I/D polymorphism and clinical efficacy of iptakalim in Chinese Han hypertensive population[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(9): 961-966.

References

[1] Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels[J]. J Clin Invest, 1990,86(4):1343-1346.
[2] Yukiko N, Tetsuya O, Hiroyuki H, et al. DD genotype of the angiotensin I-converting enzyme gene is a risk factor for early onset of essential hypertension in Japanese patients[J]. J Lab Clin Med,1998,131(6):502-506.
[3] 李冬青,王希柱,杨国强,等. ACE基因I/D和AT1R基因A1166C多态性与氢氯噻嗪降压疗效的相关性研究[J]. 山东医药,2008,48(4):19-21.
[4] 皮林,华琦,陈彪. ACE基因多态性与福辛普利降压疗效的关系[J]. 同济大学学报:医学版, 2007,28(6):30-33.
[5] Jiang X, Sheng HH, Lin G, et al. Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment[J]. Chin Med J (Engl),2007,120(9):782-786.
[6] Moraes CF, Souza ER, Souza VC, et al. A common polymorphism in the renin angiotensin system is associated with differential outcome of antihypertensive pharmacotherapy prescribed to Brazilian older women[J]. Clin Chim Acta, 2008,396(1/2):70-75.
[7] Wang H, Long CL, Zhang YL. A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension[J]. J Pharmacol Exp Ther, 2005,312(3):1326-1333.
[8] Xue H, Zhang YL, Liu GS, et al. A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in spontaneously hypertensive rats[J]. J Pharmacol Exp Ther,2005,315(2):501-509.
[9] Wang H, Tang Y, Wang L, et al. ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives[J]. Curr Med Chem, 2007,14(2):133-155.
[10] Prasad A, Narayanan S, Waclawiw MA, et al. The insertion/deletion polymorphism of the angiotensin-converting enzyme gene determines coronary vascular tone and nitric oxide activity[J]. J Am Coll Cardiol, 2000, 36(5):1579-1586.
[11] Darbar D, Motsinger AA, Ritchie MD, et al. Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation[J]. Heart Rhythm, 2007,4(6):743-749.
[12] Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease[J]. N Engl J Med, 1995,332(11):706-711.
[13] 刘国仗,胡大一,陶萍,等. 心血管药物临床试验评价方法的建议[J]. 中华心血管病杂志,1998,26(1):5-11.
[14] 范秀珍,郭歆,王华杰,等. MDR1基因C3435T多态性对替米沙坦稳态血药浓度及降压疗效的影响[J]. 中国临床药理学与治疗学,2009,14(6):670-676.
[15] 王谷亮,韩战营. 血管紧张素转换酶基因插入／缺失多态性检测方法的研究[J]. 中华心血管病杂志,2001,29(4):239-239.
[16] 刘长云,周建光,黄亚莉,等. 血管紧张素转换酶基因多态性与高血压的关系[J]. 中华航海医学与高气压医学杂志,2006,13(5):290-291.
[17] Zhang S, Mao G, Zhang Y, et al. Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension[J]. Clin Ther, 2005, 27(11):1774-1784.
[18] Trotta R, Donati MB, Iacoviello L. Trends in pharmacogenomics of drugs acting on hypertension[J]. Pharmacol Res, 2004, 49(4):351-356.
[19] Arnett DK, Claas SA. Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance[J]. Pharmacogenomics, 2009, 10(8):1295-1307.
[20] 姜远英. 药物基因组学[M]. 北京:人民卫生出版社,2006:9.
[21] Arnett DK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment[J]. 2006,44(2):107-118.